Beijing Sun-Novo Pharmaceutical Research (688621.SH) plans to raise funds of no more than 240 million yuan for the construction of projects such as the nucleic acid drug discovery and pilot testing platform research and development.
Yangguang Nuohuo (688621.SH) disclosed a plan to issue shares to specific objects through a simplified procedure for the fiscal year 2026, aiming to raise a total amount of funds not exceeding 240 million yuan (inclusive). The raised funds from the issuance will be used for: the research and development of nucleic acid drug discovery and pilot test platform construction project, and supplementing working capital.
Beijing Sun-Novo Pharmaceutical Research(688621.SH) disclosed a preliminary plan to issue shares to specific targets through a simplified procedure in 2026, intending to raise funds of no more than 240 million yuan (inclusive). The raised funds, after deducting issuance expenses, will be used for: nucleic acid drug discovery and pilot plant research and development construction projects, and supplementing working capital.
Related Articles
REF HOLDINGS (01631) granted a total of 30.72 million stock options.
Evercore ISI issued a warning ahead of PepsiCo, Inc.'s second quarter earnings report: weak consumer demand and inflation headwinds may put pressure on profits, maintaining a "keep pace with the market" rating.
HONG WEI ASIA (08191): 199 million shares of unsubscribed rights shares will be placed for sale.
REF HOLDINGS (01631) granted a total of 30.72 million stock options.
Evercore ISI issued a warning ahead of PepsiCo, Inc.'s second quarter earnings report: weak consumer demand and inflation headwinds may put pressure on profits, maintaining a "keep pace with the market" rating.
HONG WEI ASIA (08191): 199 million shares of unsubscribed rights shares will be placed for sale.
RECOMMEND
